ViiV Healthcare launches HIV Prevention Fund to support community-led initiatives in efforts to end AIDS by 2030

ViiV Healthcare is the only company 100% dedicated to combating, preventing, and ultimately curing HIV and AIDS. We know, however, that we cannot achieve our goals alone. To support communities impacted and affected by HIV, and those who are leading in the field of HIV prevention, ViiV Healthcare is launching the HIV Prevention Fund to support community-led and community-driven national and regional efforts to end AIDS by 2030. We strongly believe that engaging local communities is critical to addressing the drivers of health inequalities, and therefore strive to promote community responses that change beliefs, attitudes, and behaviours to improve health and rights at the community level.

Effective prevention strategies, including harm reduction, pre-exposure prophylaxis (PrEP), are critical in closing the gap in our collective efforts to advance the HIV response. In many countries, the epidemic continues to be concentrated among specific populations who have disproportionately low access to community-led HIV prevention programming. Furthermore, the COVID-19 pandemic has led to interruptions to HIV prevention and testing as well as HIV care and treatment services.

The HIV Prevention Fund aims to encourage prioritisation of, and investment in, HIV prevention. We are seeking applications from non-governmental organisations, community-based organisations, and patient advocacy groups, to support your advocacy efforts in ensuring HIV prevention is sufficiently prioritised in national policy/public health programmes to effectively reduce the incidence of HIV.

Applications for the Fund, which could provide grants of up to £70,000 per annum for up to two years, should address at least one of our priority funding areas and associated themes, which include:

  • Civil society driven national advocacy
  • National coordination of joint advocacy
  • Regional advocacy
  • Capacity strengthening

For more information on the application and eligibility criteria please see the ViiV Healthcare’s HIV Prevention Fund Frequently Asked Questions.

The application process will run from 18 July to 09 September 2021. Successful applicants will be announced by 01 December 2021. Funding will be dependent on the completion of relevant due diligence and verification processes.

How to apply

Applicants are required to complete an application form and submit the completed form to Applications must be in English to be considered. Proposals will be reviewed by the internal ViiV Healthcare Government Affairs and Global Public Health Grants and Donations Committee.

At ViiV Healthcare, we are focused on making HIV a smaller part of people’s lives and we are proud to continue living our mission of leaving no person with HIV behind. Through our HIV Prevention Fund, we look forward to further collaborating with the HIV community to take us one step closer to making this a reality.

Media contacts

For our corporate press office, email: Kate Senter, Director of Corporate Communications

OR call +44(0)7796 707 446

For US-specific media enquiries,email: Audrey Abernathy

OR call +1 919 605 4521

Reporting of side effects

If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at or search for MHRA Yellowcard in the Google Play or Apple App store. By reporting side effects, you can help provide more information on the safety of this medicine.

If you are from outside the UK, you can report adverse events to GSK/ViiV by selecting your region and market, here.